Rapid health technology assessment of adjuvanted recombinant herpes zoster vaccine in people over 50 years old
Objective To evaluate the efficacy,safety and economy of recombinant herpes zoster vaccine(RZV)in people over 50 years old,and provide evidence-based evidence for clinical drug selection and decision-making.Methods PubMed,Cochrane Library,Embase,CNKI,Wanfang,VIP,and rapid health technology assessment were searched.Two investigators screened the literatures,collected data and evaluated the quality according to the inclusion criteria and exclusion criteria.The results were compared qualitatively.Results Totally 13 studies were included,including 4 meta-analyses/systematic reviews and 9 economic studies.RZV had better efficacy in vaccine,preventing postherpetic neuralgia and zoster ophthalmicus,than herpes zoster live attenuated vaccine and placebo,with significant difference.In terms of safety,RZV had more adverse reactions in injection sites(including injection site redness,swelling,pain;systemic adverse events;serious adverse events and deaths),with not significant difference.In terms of economics,RZV had more economic advantages.Conclusion Based on current limited evidence,RZV is effective,safe,and economical in preventing herpes zoster and reducing the occurrence of postherpetic neuralgia and zoster ophthalmicus in people over 50 years old.Special attention should be paid to the population with low immunity when using RZV,which needs further confirmation.
recombinant herpes zoster vaccineherpes zosterrapid health technology assessment
万方数据
维普
